Noticias de COSM_US

20/04/2026 COSM_US — Weatherford Democrat

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Produ

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial…

20/04/2026 COSM_US — FinancialContent

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Produ

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial…

20/04/2026 COSM_US — The Globe and Mail

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Produ

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial…

20/04/2026 COSM_US — Investing.com

Cosmos Health to begin Liv18 liver supplement production in April

20/04/2026 COSM_US — ACCESS Newswire

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Produ

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial…

20/04/2026 COSM_US — Stock Titan

A U.S.-made liver supplement is central to Cosmos Health's $5M push

20/04/2026 COSM_US — ChartMill

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Produ

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial…

20/04/2026 COSM_US — Investing.com

Cosmos Health to begin Liv18 liver supplement production in April By Investing.com

18/04/2026 COSM_US — GuruFocus

Cosmos Health (COSM) Unveils Innovative Curcumin Supplement for U.S. Market

17/04/2026 COSM_US — Investing.com ES ← EN

Cosmos Health amplía la integración de la IA en todas las operaciones Por Investing.com

17/04/2026 COSM_US — Investing.com

Cosmos Health plans Q2 U.S. launch of curcumin supplement By Investing.com

17/04/2026 COSM_US — The Batesville Daily Guard

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

17/04/2026 COSM_US — The Daily Corinthian ES ← EN

Cosmos Health continúa su expansión en EE. UU. con el lanzamiento en el segundo trimestre de Cur18, un suplemento terapéutico de curcumina de próxima generación patentado y clínicamente estudiado que ofrece una biodisponibilidad 39 veces mayor y está diseñado para respaldar la salud de las articulaciones

Cosmos Health continúa su expansión en EE. UU. con el lanzamiento en el segundo trimestre de Cur18, un suplemento terapéutico de curcumina de próxima generación patentado y clínicamente estudiado que…

17/04/2026 COSM_US — ChartMill

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

17/04/2026 COSM_US — Yahoo Finance

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

17/04/2026 COSM_US — Investing.com India

Cosmos Health plans Q2 U.S. launch of curcumin supplement By Investing.com

17/04/2026 COSM_US — Investing.com

Cosmos Health plans Q2 U.S. launch of curcumin supplement

17/04/2026 COSM_US — Stock Titan

A turmeric supplement with 39x absorption heads to the U.S. in Q2

17/04/2026 COSM_US — ACCESS Newswire

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health